Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database

Key Points

• Hematologic adverse events were found to be significantly related to trastuzumab deruxtecan.
• Using disproportionality analysis on the Japanese pharmacovigilance database reveals key findings.
• The study identifies specific blood-related side effects from trastuzumab deruxtecan across multiple reports.
• Highlights the need for ongoing safety monitoring to understand these adverse effects.